BACKGROUND: Hyperlipidemia is a known risk factor for the development of atherosclerosis and coronary artery disease in morbidly obese individuals. The aim of our study was to review the trends in the serum lipid profiles of patients undergoing Roux-en-Y gastric bypass at our institution. METHODS: A retrospective 6-year analysis of data of patients undergoing Roux-en-Y gastric bypass was performed. The indicators of resolution of hyperlipidemia were reviewed for 6 months and then annually for 6 consecutive years. Hyperlipidemia was defined according to the American Heart Association and National Cholesterol Education Program Adult Treatment Panel III guidelines. The changes in the lipid profile of the patients with subnormal levels of high-density lipoprotein (HDL) cholesterol and total cholesterol/HDL cholesterol risk ratio were also examined. RESULTS: A total of 94 patients were diagnosed with hyperlipidemia, of whom 23 were receiving clinical treatment. The mean patient age was 39 ± 9 years, and the mean body mass index was 50 ± 9.6 kg/m(2), with a female predominance. The mean baseline serum levels were as follows: total cholesterol 220 ± 42.2 mg/dL, triglycerides 212 ± 123.5 mg/dL, low-density lipoprotein cholesterol 135 ± 34.2 mg/dL, and HDL cholesterol 51 ± 12 mg/dL. The optimization of serum total cholesterol, triglycerides, and low-density lipoprotein cholesterol profiles was seen in all patients within 6 months after surgery. The HDL cholesterol levels improved more slowly, reaching desirable levels within 12 months after surgery. All patients taking lipid-lowering agents no longer required the medication at the end of the study period. CONCLUSION: Roux-en-Y gastric bypass provides an effective remission of hyperlipidemia in morbidly obese patients, with most patients no longer requiring lipid-lowering agents within 6 months after surgery. The improvement in overall lipid profiles continued during follow-up after surgery.
BACKGROUND:Hyperlipidemia is a known risk factor for the development of atherosclerosis and coronary artery disease in morbidly obese individuals. The aim of our study was to review the trends in the serum lipid profiles of patients undergoing Roux-en-Y gastric bypass at our institution. METHODS: A retrospective 6-year analysis of data of patients undergoing Roux-en-Y gastric bypass was performed. The indicators of resolution of hyperlipidemia were reviewed for 6 months and then annually for 6 consecutive years. Hyperlipidemia was defined according to the American Heart Association and National Cholesterol Education Program Adult Treatment Panel III guidelines. The changes in the lipid profile of the patients with subnormal levels of high-density lipoprotein (HDL) cholesterol and total cholesterol/HDL cholesterol risk ratio were also examined. RESULTS: A total of 94 patients were diagnosed with hyperlipidemia, of whom 23 were receiving clinical treatment. The mean patient age was 39 ± 9 years, and the mean body mass index was 50 ± 9.6 kg/m(2), with a female predominance. The mean baseline serum levels were as follows: total cholesterol 220 ± 42.2 mg/dL, triglycerides 212 ± 123.5 mg/dL, low-density lipoprotein cholesterol 135 ± 34.2 mg/dL, and HDL cholesterol 51 ± 12 mg/dL. The optimization of serum total cholesterol, triglycerides, and low-density lipoprotein cholesterol profiles was seen in all patients within 6 months after surgery. The HDL cholesterol levels improved more slowly, reaching desirable levels within 12 months after surgery. All patients taking lipid-lowering agents no longer required the medication at the end of the study period. CONCLUSION: Roux-en-Y gastric bypass provides an effective remission of hyperlipidemia in morbidly obesepatients, with most patients no longer requiring lipid-lowering agents within 6 months after surgery. The improvement in overall lipid profiles continued during follow-up after surgery.
Authors: Daniel Gero; Lucie Favre; Pierre Allemann; Pierre Fournier; Nicolas Demartines; Michel Suter Journal: Obes Surg Date: 2018-03 Impact factor: 4.129
Authors: E Griffo; G Nosso; R Lupoli; M Cotugno; G Saldalamacchia; G Vitolo; L Angrisani; P P Cutolo; A A Rivellese; B Capaldo Journal: Obes Surg Date: 2014-05 Impact factor: 4.129